Neither you nor your doctor are able to decide which group you are in.
Lenvatinib and pembrolizumab
You have:
You continue lenvatinib and pembrolizumab for as long as it helps you and the side effects aren’t too bad. You can have treatment for up to 2 years.
After 2 years, you may be able to continue having treatment for another year. This is called the second course treatment. Your doctor can tell you more about this.
Doxorubicin or paclitaxel
You have doxorubicin or paclitaxel as a drip into your vein over an hour. You have:
- doxorubicin every 3 weeks
- paclitaxel every week for 3 weeks, followed by a week off
Your doctor can tell you which treatment you have. This continues for as long as treatment is helping you and the side effects aren’t too bad.
Blood tests
You have extra blood tests as part of this trial. You have them before the start of treatment and then:
- every 3 or 4 weeks
- at the end of treatment
Doctors want to look for certain proteins (biomarkers) that can tell how well the treatment is working. And find out what happens to lenvatinib in your body (pharmacokinetics).
Tissue sample
The trial team ask to use a tissue sample of your cancer taken when you had surgery or a biopsy. You need to have a new sample taken if there isn’t a suitable sample available.
Researchers want to look for certain changes (mutations) in a gene called the mismatch repair gene.
Quality of life
- every 3 to 4 weeks
- at the end of treatment
- a month after finishing treatment
The questionnaires ask about how you have been feeling and what side effects you have had.